Tracking a new psoriasis treatment in real patients
NCT ID NCT07256015
Summary
This study follows 200 Italian patients with moderate to severe psoriasis who have recently started taking the medication deucravacitinib. Researchers want to see how well the drug works, how safe it is, and how it affects patients' quality of life in a real-world setting, outside of a controlled clinical trial. The goal is to understand the drug's real-life performance for managing this chronic skin condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Azienda Ospedaliera Universitaria Integrata Di Verona
RECRUITINGVerona, Verona, 37126, Italy
Contact
Conditions
Explore the condition pages connected to this study.